Rivastigmine Patch, Extended Release
Product Images NDC 0781-7309

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 0781-7309). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 01

Chemical structure of rivastigmine, the active ingredient in the Rivastigmine transdermal patch. The diagram shows the molecular arrangement of atoms and bonds characteristic of rivastigmine's chemical composition.*

FDA Label Image

Image 02

An illustration showing a cross-sectional view of a rivastigmine transdermal patch with four labeled layers stacked vertically. The image includes labels for simple dimples on both ends of the patch structure, likely indicating fastening or adhesive points.*

FDA Label Image

Image 03

Line graph showing plasma rivastigmine concentration (ng/mL) over 24 hours following administration of rivastigmine transdermal patches at doses of 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. Different symbols represent each dose group, with concentration increasing then gradually declining over time for each strength.*

FDA Label Image

Image 04

A line graph showing least square means with SEM change from baseline ADAS-Cog ratings over 24 weeks of treatment. The graph compares clinical improvement and decline among four groups: 17.4 mg/24 hours, 9.5 mg/24 hours, 6 mg capsules BID, and placebo. The x-axis represents weeks during treatment, and the y-axis indicates change in ADAS-Cog rating.*

FDA Label Image

Image 05

A bar chart comparing the percentage of patients across different treatment groups based on the ADCS-CGIC rating. Groups include 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo. The ratings range from markedly improved to markedly worse, showing distribution of patient responses for each treatment.*

FDA Label Image

Image 06

A line graph depicting the ADCS-ADL change from baseline over 48 weeks of treatment for Rivastigmine Transdermal System at 13.3 mg/24hr and 9.5 mg/24hr doses. The y-axis shows clinical improvement to decline, and the x-axis shows weeks of treatment. The 13.3 mg/24hr dose shows less decline over time compared to the 9.5 mg/24hr dose, with statistical significance indicated at several points.*

FDA Label Image

Image 07

A line graph displaying the ADAS-Cog change from baseline over weeks of treatment for Rivastigmine Transdermal System patches at 13.3 mg/24hr and 9.5 mg/24hr doses. The vertical axis indicates clinical improvement or decline, and the horizontal axis shows weeks from 0 to 48. The graph compares cognitive changes with data points and error bars for both dosages over time.*

FDA Label Image

Image 08

A line graph comparing least squares mean change plus or minus standard error over 24 weeks of treatment for two types of Rivastigmine patches (15 cm² and 5 cm²). The vertical axis shows LS mean change from 3.0 to -8.0, while the horizontal axis shows weeks of treatment from 0 to 24. The graph includes statistical annotations with p-values and confidence intervals, indicating significant clinical improvement for the 15 cm² patch compared to the 5 cm² patch over time.*

FDA Label Image

Image 09

A line graph depicting the least squares (LS) mean change with standard errors over 24 weeks of treatment for Rivastigmine patches of 15 cm² and 5 cm² sizes. The y-axis shows LS mean change with values from -8 to 3, indicating clinical improvement or decline. Data points for weeks 0, 8, 16, and 24 show decreasing LS mean values for both patch sizes, with p-values and confidence intervals noted above each time point for statistical significance.*

FDA Label Image

Image 10

An illustration diagram showing the Rivastigmine Transdermal System patch packaging and components. It depicts a labeled pouch containing the patch, the patch with protective liners on both sides, and an exploded view of the patch showing the adhesive with medicine and the outside backing. The labeler is Sandoz Inc.*

FDA Label Image

Image 11

Instructional diagram depicting possible application sites for a transdermal rivastigmine patch on the human body. Shaded rectangular areas indicate placement options on the left or right upper arm (side view), left or right side of chest (front view), left or right upper back (back view), and left or right lower back (back view).*

FDA Label Image

Image 12

Illustration showing a hand holding a Rivastigmine Transdermal System patch being cut with scissors. The patch packaging is labeled for transdermal use only and contains one system. The labeler Sandoz Inc is visible.*

FDA Label Image

Image 13

An instructional illustration shows two hands peeling protective liners away from a circular transdermal patch, exposing the sticky surface of the patch. Labeled arrows identify the "Protective Liners" and the "Sticky surface of patch." The image visually demonstrates how to remove the liners before applying the patch to skin.*

FDA Label Image

Image 14

An instructional diagram showing how to apply a rivastigmine extended-release transdermal patch to the upper back of a person. The illustration depicts hands placing the patch onto the skin, demonstrating correct application technique.*

FDA Label Image

Image 15

An instructional illustration showing the application of a transdermal patch to the upper back, near the shoulder blade, on a person's skin. The drawing features a hand placing the patch, demonstrating correct placement for a rivastigmine transdermal patch.*

FDA Label Image

Image 16

An instructional diagram showing placement of a transdermal patch on the upper chest by a person using one hand to peel the patch from its backing and the other hand to apply it to the skin. This illustrates correct application of a rivastigmine extended-release transdermal patch.*

FDA Label Image

Image 17

An instructional three-panel illustration showing the proper disposal method for a Rivastigmine transdermal patch. The first panel depicts folding the sticky sides of the patch together. The second shows sliding the folded patch into a pouch for saving. The third panel advises placing the patch in the trash and keeping it away from children and pets.*

FDA Label Image

Image 18

Rivastigmine Transdermal System 4.6 mg/24 hours extended-release patch packaging label. The label shows this prescription drug is for transdermal use only and each system delivers 4.6 mg over 24 hours. The box contains 30 systems and is labeled by Sandoz Inc. Instructions for discarding the used patch are provided, emphasizing safety and hygiene.*

FDA Label Image

Image 19

Rivastigmine Transdermal System packaging label from Sandoz Inc features dosage strengths of 0.3 mg/24 hours and 9.5 mg/24 hours. The label indicates it is for transdermal use only, prescription use, and contains 30 systems. Instructions for discarding the patch safely are also included on the packaging.*

FDA Label Image

Image 20

Packaging label for Rivastigmine Transdermal System 13.3 mg/24 hours by Sandoz Inc. The label indicates it is a transdermal patch for prescription use only, delivering the active ingredient rivastigmine at 13.3 mg per 24 hours. The package contains 30 systems. Instructions for patch removal and disposal are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.